Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life.
Journal
Clinical and molecular allergy : CMA
ISSN: 1476-7961
Titre abrégé: Clin Mol Allergy
Pays: England
ID NLM: 101152195
Informations de publication
Date de publication:
19 May 2022
19 May 2022
Historique:
received:
24
02
2022
accepted:
13
04
2022
entrez:
19
5
2022
pubmed:
20
5
2022
medline:
20
5
2022
Statut:
epublish
Résumé
Biologics are currently one of the main treatment options for a number of diseases. The IgG4 monoclonal antibody dupilumab targets the Interleukin-4 receptor alpha chain, thus preventing the biological effects of the cytokines IL-4 and IL-13, that are essential for the Th2 response. Several controlled trials showed that dupilumab is effective and safe in patients with atopic dermatitis (AD), severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), thus resulting in approval by regulatory agencies. Aim of the study was to evaluate the efficacy and safety of dupilumab in adult patients with CRSwNP stratified by common overlapping comorbid conditions. We performed a multicenter, observational, prospective study enrolling adult patients with severe CRSwNP who had started dupilumab treatment in the context of standard care from January 2021 to October 2021. Data were collected from twentynine Italian secondary care centers for allergy and clinical immunology, all of which were part of the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). A number of efficacy parameters were used. Patient data were compared using the Wilcoxon test for paired data. All statistical analyses were performed with SPSS version 20 (IBM, Armonk, NY, USA). In total, 82 patients with nasal polyposis were identified. A significant improvement was detected for all the applied efficacy parameters, i.e. 22-item Sino-Nasal Outcome Test (SNOT-22) and bilateral endoscopic nasal polyp score (NPS) scores for CRSwNP, Rhinitis Control Scoring System (RCSS) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores for allergic perennial rhinitis, Forced Expiratory Volume in the 1st second (FEV1) and Asthma Quality of Life Questionnaire (AQLQ) scores for asthma, Eczema Area and Severity Index (EASI) and Dermatology Life Quality Index (DLQI) scores for AD. A non-significant improvement was also obtained in the Urticaria Activity Score over 7 days (UAS7) for chronic spontaneous urticaria. Treatment with dupilumab was well tolerated. These data suggest that dupilumab treatment in patients suffering from CRSwNP and associated comorbidities may be suitable. Such outcome, although confirmation by trials is warranted, suggests the possibility to treat different disorders with a single therapy, with favorable effects especially under the cost-effectiveness aspect.
Sections du résumé
BACKGROUND
BACKGROUND
Biologics are currently one of the main treatment options for a number of diseases. The IgG4 monoclonal antibody dupilumab targets the Interleukin-4 receptor alpha chain, thus preventing the biological effects of the cytokines IL-4 and IL-13, that are essential for the Th2 response. Several controlled trials showed that dupilumab is effective and safe in patients with atopic dermatitis (AD), severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), thus resulting in approval by regulatory agencies. Aim of the study was to evaluate the efficacy and safety of dupilumab in adult patients with CRSwNP stratified by common overlapping comorbid conditions.
METHODS
METHODS
We performed a multicenter, observational, prospective study enrolling adult patients with severe CRSwNP who had started dupilumab treatment in the context of standard care from January 2021 to October 2021. Data were collected from twentynine Italian secondary care centers for allergy and clinical immunology, all of which were part of the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). A number of efficacy parameters were used. Patient data were compared using the Wilcoxon test for paired data. All statistical analyses were performed with SPSS version 20 (IBM, Armonk, NY, USA).
RESULTS
RESULTS
In total, 82 patients with nasal polyposis were identified. A significant improvement was detected for all the applied efficacy parameters, i.e. 22-item Sino-Nasal Outcome Test (SNOT-22) and bilateral endoscopic nasal polyp score (NPS) scores for CRSwNP, Rhinitis Control Scoring System (RCSS) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores for allergic perennial rhinitis, Forced Expiratory Volume in the 1st second (FEV1) and Asthma Quality of Life Questionnaire (AQLQ) scores for asthma, Eczema Area and Severity Index (EASI) and Dermatology Life Quality Index (DLQI) scores for AD. A non-significant improvement was also obtained in the Urticaria Activity Score over 7 days (UAS7) for chronic spontaneous urticaria. Treatment with dupilumab was well tolerated.
CONCLUSIONS
CONCLUSIONS
These data suggest that dupilumab treatment in patients suffering from CRSwNP and associated comorbidities may be suitable. Such outcome, although confirmation by trials is warranted, suggests the possibility to treat different disorders with a single therapy, with favorable effects especially under the cost-effectiveness aspect.
Identifiants
pubmed: 35590407
doi: 10.1186/s12948-022-00171-2
pii: 10.1186/s12948-022-00171-2
pmc: PMC9121619
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6Informations de copyright
© 2022. The Author(s).
Références
J Eur Acad Dermatol Venereol. 2019 May;33(5):918-924
pubmed: 30451325
Hum Exp Toxicol. 2015 Dec;34(12):1279-85
pubmed: 26614816
J Am Acad Dermatol. 2018 Jan;78(1):62-69.e1
pubmed: 28987493
Rhinol Suppl. 2012 Mar;23:3 p preceding table of contents, 1-298
pubmed: 22764607
HNO. 2021 Nov;69(11):868-877
pubmed: 33738558
J Dermatol Sci. 2018 May;90(2):190-198
pubmed: 29472119
J Am Acad Dermatol. 2004 Mar;50(3):391-404
pubmed: 14988682
Respir Res. 2019 May 31;20(1):108
pubmed: 31151443
Cochrane Database Syst Rev. 2021 Mar 12;3:CD013513
pubmed: 33710614
Allergy. 2001 Sep;56(9):915
pubmed: 11551260
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):1797-1810
pubmed: 33991374
Int J Mol Sci. 2021 Dec 30;23(1):
pubmed: 35008843
Dermatol Ther. 2021 Mar;34(2):e14821
pubmed: 33506984
J Allergy Clin Immunol. 2009 Oct;124(4):719-23.e1
pubmed: 19767070
J Eur Acad Dermatol Venereol. 2021 Apr;35(4):958-964
pubmed: 33332697
Allergol Immunopathol (Madr). 2017 Dec;45 Suppl 1:45-49
pubmed: 29108767
Respir Med. 2005 May;99(5):553-8
pubmed: 15823451
Clin Exp Allergy. 2020 Jan;50(1):5-14
pubmed: 31505066
Ann Allergy Asthma Immunol. 2019 Sep;123(3):232-239
pubmed: 31295554
J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1659-1661.e1
pubmed: 30496828
Allergy. 2020 Oct;75(10):2653-2661
pubmed: 32424957
Dermatol Ther (Heidelb). 2017 Dec;7(4):493-505
pubmed: 28933010
Eur Respir J. 1999 Oct;14(4):902-7
pubmed: 10573240
J Asthma. 2019 Oct;56(10):1110-1119
pubmed: 30273510
J Am Acad Dermatol. 2021 Jan;84(1):139-147
pubmed: 32822798
Expert Rev Clin Immunol. 2017 May;13(5):425-437
pubmed: 28277826
Allergy Asthma Immunol Res. 2021 Mar;13(2):347-349
pubmed: 33474867
Clin Otolaryngol. 2009 Oct;34(5):447-54
pubmed: 19793277
J Clin Epidemiol. 1994 Jan;47(1):81-7
pubmed: 8283197
Int Immunopharmacol. 2018 Jan;54:303-310
pubmed: 29182975
J Investig Allergol Clin Immunol. 2020;30(6):448-450
pubmed: 32376512
Clin Exp Allergy. 2020 Jul;50(7):789-798
pubmed: 32469092
Arerugi. 2020;69(10):979-988
pubmed: 33310981
Allergy. 2021 Feb;76(2):593-596
pubmed: 33017860
Am J Clin Dermatol. 2018 Apr;19(2):145-165
pubmed: 29098604
J Allergy Clin Immunol. 2017 Sep;140(3):888-891.e6
pubmed: 28479326